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Background: Atorvastatin calcium (ATC), an anti-lipid biopharmaceutical class II drug, is widely prescribed as a
cholesterol-lowering agent and is presently the world’s best-selling medicine. A large number of crystalline forms of
ATC have been published in patents. A variety of solid forms may give rise to different physical properties.
Therefore, the discovery of new forms of this unusual molecule, ATC, may still provide an opportunity for further
improvement of advantageous properties.
Results: In the present work, eight new solvates (Solvate I-VIII) have been discovered by recrystallization method.
Thermal behaviour of ATC and its solvates studied by DSC and TGA indicate similar pattern suggesting similar
mode of entrapment of solvent molecules. The type of solvent present in the crystal lattice of the solvates is
identified by GC-MS analysis and the stoichiometric ratio of the solvents is confirmed by 1HNMR. The high positive
value of binding energy determined from thermochemical parameters indicates deep inclusion of the solvent
molecules into the host cavity. The XRPD patterns point towards the differences in their crystallanity, however, after
desolvation solvate II, III, IV, V and VIII transform to isostructral amorphous desolvated solvates. The order of
crystallinity was confirmed by solution calorimetric technique as the enthalpy of solution is an indirect measure of
lattice energy. All the solvates behaved endothermically following the order solvate-VIII (1-butanol solvate) <
solvate-I (isoproplyate) < solvate-V (methanol solvate) < solvate-III (ethonalate) < solvate-VI (acetone ethanol
solvate) < solvate-IV (t-butanol solvate) < solvate-II (THF solvate) < solvate-VII (mixed hemi-ethanol hydrate). The
positive value of the heat capacity of the solvate formation provides information about the state of solvent
molecules in the host lattice. The solvents molecules incorporated in the crystal lattice induced local chemical
environment changes in the drug molecules which are observed in 13CP/MAS NMR spectral changes.
Conclusions: Aqueous solubility of solvate-VIII was found to be maximum, however, solvate-I and VIII showed
better reduction in total cholesterol and triglyceride levels as compared to atorvastatin against triton-induced
dyslipidemia.
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Active pharmaceutical ingredients as well as excipients
may exist in different solid forms which is of great impor-
tance for pharmaceutical development [1]. One important
type of solid forms are solvates. Over the past decade, ma-
ny different solvates of pharmaceutical materials with rea-
dily discernible physical and chemical characteristics, and* Correspondence: renukchadha@rediffmail.com
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distribution, and reproduction in any mediummarked differences in their pharmaceutical performance
have appeared. Solvates are defined as crystalline multi-
component system in which a solvent(s) is accommodated
by the crystal structure in stoichiometric and non-stoi-
chiometric manner [2]. The formation of organic solvates
instead of hydrates plays a significant role since the phar-
maceutical substances are often exposed to organic sol-
vent during production and processing. In addition, the
transformation behaviour of solvates during crystallization
and storage is often complicated and difficult to under-
stand completely. The relative stability of the solvated andtral Ltd. This is an Open Access article distributed under the terms of the
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http://journal.chemistrycentral.com/content/6/1/114non-solvated forms depends upon the temperature, pres-
sure and thermodynamic activity of the solvent. Therefore,
a study of these considerations is important in order to
design or control a process that yields a solid form with
the desired properties. The isostructural unsolvated form
generated by desolvation is called isomorphic desolvate or
desolvated solvate [2]. Hence, the screening for various
crystal modifications has been increasingly emphasized in
pharmaceutical industry as it provides valuable knowledge
necessary for further development of the drug formulation
[3-5].
Atorvastatin, 3-hydroxy-3-methyl-glutaryl-coenzyme A
(HMG-CoA) reductase inhibitor (Figure 1), a cholesterol-
lowering agent for the treatment of hypercholesterolemia
is a synthetic statin, which catalyzes the rate-limiting step
in cholesterol biosynthesis. Atorvastatin is marketed as
its calcium salt in crystalline trihydrate. However, the sky
soaring demand of ATC and an interesting structure of
this drug directed the pharmaceutical scientist towards a
high number of patents and many publications offering
different crystalline forms as well as processes to generate
alternative forms [6]. A variety of solid forms may give rise
to different physical properties. The successful utilization
of a crystal form of significantly greater thermodynamic
activity (i.e., solubility) than the stable modification may
provide, in some instances, therapeutic blood levels from
otherwise inactive drugs [7-10]. However, ATC, belongs to
an anti-lipid class II drug, not more emphasis have been
laid to determine the solubility of the new form generated.
Besides these none of the publications report the in-vivo
activity of the new recrystalised forms. Therefore, the dis-
covery of new crystalline solvates of this unusual mol-
ecule, ATC, may still provide an opportunity for further
improvement of advantageous properties. Thus the pre-
sent investigation deals with the preparation of different
solvates of ATC by solvent recrystallization method and to
characterize them using established solid state and solu-
tion phase techniques. The solvates are further evaluated
by in-vivo studies using Triton induced hyperlipidemia to
select the most suitable solvate. The objective was to gainFigure 1 Molecular structure of ATC molecule, showing the numberina better understanding of the solid state behaviour of ATC
solvates before and after desolvation which might enable
the development of a more consistent and efficacious
ATC oral formulation.
Results and discussion
The various forms of ATC were subjected to different
techniques for their exact characterization. TGA pro-
vides insight about the amount of solvent actually pre-
sent and DSC provides information on the energetics, of
how it interacts within the crystal lattice of parent mo-
lecule [11]. As all the solvates have been obtained by
recrystallization using more than one solvent and one or
two step desolvation has been observed in the TGA, it
was necessary to confirm the type of solvent associated
with the drug molecule. To confirm this, GCMS analysis
has been performed [12]. Initial characterization and stoi-
chiometry of the various solvates have been established by
DSC, TGA, GCMS and 1H NMR analysis. Existence of
solvents were further confirmed by 13C /MAS solid state
NMR.
Characterization by Differential Scanning Calorimetry
(DSC), Thermogravimetric Analysis (TGA), GCMS and
Karl-Fisher analysis
TGA analysis of ATC and its different forms at heating
rate of 10°C/min (Figure 2) was studied to elucidate the
mass loss associated with the thermal transitions. The
commercial sample revealed three steps mass loss in the
temperature range 40-100°C, 105-140°C and 170-260°C
respectively. The first step temperature range indicates it
to be loosely bound water. Subsequently, the second step
is associated with loss of water of hydration followed
by total mass loss (above 210°C) due to its degradation.
Total mass loss of 4.44% for the first two steps confirm
it to be a trihydrate and corresponds to ATC-1 as des-
cribed [13]. The DSC curve of commercial atorvastatin
at 10°C/min exhibited a broad endotherm ranging from
70-140°C indicating the loss of water and a sharp en-
dotherm at 162.78°C (Figure 3) which is due to meltingg of the carbons and nitrogen.
Figure 2 TGA of ATC and its solvates.
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of ATC confirm it to be a trihydrate which melts at
162.78°C.
The TGA of solvates I, II, III, IV, V and VIII showed
mass loss in two steps. The first step in the range 40-
120°C corresponds to desolvation whereas the second
dip is associated with decomposition of the solvates. The
DSC thermograms of the prepared solvates showed a
single broad endothermic peak with slight variation in
onset temperatures followed by not so sharp melting
endotherms. Mass losses of 2.44% in TGA of solvate-I
suggest 0.5 mole of isopropyl alcohol per mole of the
host compound. The broad endothermic peak of solvate-I
in the temperature range 40-105°C corresponds to deso-
lvation and a second endotherm at 155.3°C with a signifi-
cantly lower ΔHm of 8.03 J/g indicate melting. Solvate-I is
obtained from isopropyl alchocol, acetone and water asanti-solvent is subjected to GCMS analysis to ascertain
the type of solvent present in the lattice. A single peak
at 2.28 min corresponding to the retention time for iso-
propyl alcohol is obtained. This suggests that solvate-I
contain isopropyl alcohol while acetone is not associated
with the crystal lattice. Besides this, incorporation of water
from the recrystallization solvent was ruled by Karl-Fisher
analysis. This was immediately followed by decompos-
ition. The above analysis reveals it to be isopropyl alcohol
solvate.
A mass loss of 5.5% (55-130°C), 2.7% (50-120°C) and
3.6% (50-110°C) has been demonstrated in the TGA plots
of solvate II, III and IV respectively. In the DSC thermo-
grams of solvate II, III (obtained from ethanol) and IV
two endothermic events have been observed, a flat and
broad one at lower temperature followed by somewhat
sharper one. The flat and broad endothermic peaks were
Figure 3 DSC thermograms of ATC and its solvates.
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http://journal.chemistrycentral.com/content/6/1/114observed with a maxima at 90(±8)°C due to solvent loss
as suggested by TGA. The desolvation is succeeded by
a small endothermic peak prior to the melting and is
attributed to solid-solid phase transition (molecular re-
orientation) to a new polymorphic form which melts at
158°C, 165°C and 140°C in solvate II, III and IV respect-
ively as no mass loss has been observed in this range inTGA. In the similar way, in GCMS analysis of solvate-II
(obtained from THF) showed a retention time at 2.32 min
which corresponds to retention time for THF. Solvate-IV
(obtained from t-butanol using toluene as antisolvent)
showed major peak at 2.73 min analogous to retention
time for t-butanol. The desolvation temperature ranges
and the percent mass loss in TGA for these three solvates
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solvates respectively with 1:1 host to guest stoichiometry
(Table 1). The solvate-IV is a tert-butanol solvate with 2:1
stoichiometry.
The solvate-V (obtained from methanol) showed broad
desolvation endotherm in the temperature range 41.07°C −
105.8°C accompanied by mass loss of 3.16% in TGA. Ta-
king into consideration from TGA this form is found to
be a methanol solvate with 1: 1 stoichiometry.
A three step mass loss is indicated in solvate VI and
VII, where the first two steps correspond to desolva-
tion as these occur around 50-120°C and the third step
around 200°C might be due to degradation. The solvate-
VI and VII revealed broad desolvation endotherms with
maxima at 72.5°C and 105.1°C accompanied by two step
mass loss of 4.25%/1.89% for solvate-VI and 1.87%/
2.07% for solvate-VII in the TGA. Solvate-VI (obtained
from acetone, THF and ethanol) showed two major
peaks eluting at 1.57 min and 1.64 min in the GCMS
analysis. It was easily concluded that the solvents asso-
ciated with solvate-VI were ethanol and acetone [14].
Solvate-VII (obtained from ethanol and water as an anti-
solvent) showed major peak at 1.57 min which corre-
sponds to retention time for ethanol. As water has been
used as anti-solvent the Karl-Fisher(KF) analysis was
used to determine the water content if present. KF ana-
lysis indicated that the sample contained 1.48% water.
The calculations suggest solvate VI to be a 2:2:1 acetone:
ethanol solvate, while solvate-VII is a mixed water:etha-
nol solvate with 2:2:1 stoichiometry.Table 1 Thermodynamic parameters obtained from differenti













Atorvastatin (ATC) - 162.78 68.05
Solvate- I (ATC + 0.5
Isopropyl alcohol)
84.71 155.3 8.03 2.44
Solvate- II (ATC + THF) 98.89 158.43 8.86 5.47
Solvate- III (ATC +
Ethanol)
90.42 165.30 3.775 2.73
Solvate- IV (ATC + 0.5
t-butanol)
83. 34 140.97 3.58 3.58
Solvate- V (ATC +
methanol)
70.15 124.85 36.00 5.85
Solvate-VI (ATC + 1
Acetone +0.5 Ethanol)
72.53 172.30 32.66 5.66
Solvate-VII (ATC + 0.5
Ethanol + Water)
105.13 160.70 9.060 3.94
Solvate- VIII (ATC + 1-
butanol)
119. 5 164.8 27.16 6.12Solvate-VIII (obtained from mixture of ACN, isopropy-
lalcohol and 1-butanol) showed elution peak at 2.80 min
in GCMS analysis corresponding retention time for buta-
nol, confirming the presence of butanol in the crystal. The
solvate-VIII show desolvation endotherm at 119.5°C and
an accompanying mass loss of 6.12% in TGA. The calcula-
tion shows that solvate-VIII is butanol solvate with 1:1
stiochiometry.
1H NMR analysis
To confirm the identity and proportion of solvent of
crystallization, all the solvates were subjected for 1H
NMR analysis [15]. The 1H NMR of ATC showed total
signals for 32 protons (1H NMR corresponding to each
form are provided in the Additional file 1: Figure S1).
The 1H NMR of solvate I showed a signal merged with
–CH (position 9) proton of ATC at 3.33 and an extra
doublet at δ1.10, integrating one and three protons res-
pectively which confirmed the presence of half mole of
isopropyl alcohol in solvate I. However, 1H NMR of solv-
ate II showed signals for THF at δ3.32 and at δ2.09 inte-
grating a total of eight protons. These peaks can be
accounted for one mole of entrapped solvent in the crys-
tal of ATC-THF solvate. Regarding solvate III an extra
quartet integrating two protons at δ3.54 and an extra
triplet at δ1.10 integrating three protons confirmed pres-
ence of one mole of ethanol in solvate. The 1 H NMR of
solvate IV revealed singlet at δ1.25 integrating nine pro-
tons of t-butanol. Both hemiethanol hydrate and Metha-
nol showed broad signals merged with –CH (position 8)al scanning calorimetry and thermogravimetric analysis














2.57 2.88 44.00 141.41
5.86 2.32 32.47 55.17
2.83 - 38.61 63.34
3.11 2.73 37.89 136.63
5.31 - 35.31 54.90
6.53 1.64 31.30 65.63
1.57 38.61
4.37 1.57 38.61 106.61
40.67
6.59 2.80 43.29 61.46
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These integrate to two and three protons respectively
confirming the association of half mole of ethanol and
one mole of methanol in solvate VII and solvate V crys-
tals respectively. Similarly 1HNMR of solvate VI showed
an extra quartet at δ3.37 and an extra singlet at δ2.10
integrating two and six protons respectively. These sig-
nals can be accounted for half mole of ethanol and one
mole of acetone in solvate. Similarly 1 H NMR of buta-
nol showed an extra triplet integrating two protons at
δ3.48, broad signal merged with –CH3 (position 12) pro-
tons of ATC integrating two protons at δ1.45, sextet in-
tegrating two protons at δ1.35 and triplet integrating
three protons at δ0.90 respectively. These signals con-
firmed presence of one mole of butanol in solvate VIII
crystals. Thus, the stoichiometry established by TGA
and GCMS is confirmed by 1H NMR analysis. The re-
sults are shown in Table 1.
Determination of binding energy of solvates
The desolvation temperatures account for the stability
of solvates as the desolvation temperature in all these
forms is much higher than the boiling point of the cor-
responding solvent. The quantitative estimate of the sta-
bility of these solvates is established by determining the
binding energy [1,14,16] for the solvents in all the solvates
using equation 1 where the percent mass loss measured
over the TG desolvation step of each solvate (ΔmS%) was
related to the enthalpy change calculated over the corres-
ponding DSC desolvation endotherm (ΔHSexp).
ΔHS ¼ ΔHS exp  100
 
Δms%
   Ms ð1Þ
where ΔHS (J mol
-1) is the enthalpy of desolvation (or
binding energy) per mole of the bound solvent, MS is the
molecular mass of the solvent.
The calculated values of binding energies are given in
the Table 1 and are compared with their corresponding
enthalpy of vaporization. It can be seen that in all the
cases the solvent molecules are strongly bound com-
pared to their interactions in the liquid state suggesting
the solvent molecules are tightly bound into the host
molecule.
Scanning electron microscopy
Scanning electron microscopy was used to clarify the
surface and shape (morphology) characteristics of the
forms prepared. The SEM photographs show that the
crystal particles of all the solvates were reduced to very
small size (1–10 μm). The solvate-I and II showed ir-
regular crystal structure and their surfaces were found
to be uneven (Figure 4). The crystal shapes of all other
solvates except solvate-VIII were not clearly defined and
the appearance of both small and large particles isevident from the photomicrographs. Electron micros-
copy observations of solvate-VII showed more irregular
crystals in habit but more uniform in size. The particles
of solvate-VIII showed discrete, smooth, uniformly sized
spherical appearance. The smooth surfaces and homoge-
neous morphology is further confirmed by the broade-
ning of peaks in XRPD and 13C /MAS solid state NMR
analysis.XRPD
It is well known that XRPD is a powerful technique for
the identification of crystalline and non-crystalline pha-
ses. This technique therefore was employed to establish
differences in prepared solvates [11]. The XRPD pattern
of ATC is characterized with a high degree of crystalli-
nity as can be seen in Figure 5.
The XRPD pattern of solvate-I and II are readily dis-
tinguishable from all other solvates. Moreover, the pos-
ition of peaks in the range 5-30 differentiate solvate-I
that of solvate-II. The weak and broad nature of peaks
indicated low crystalline nature of the forms. However,
the XRPD spectra in all other solvates except solvate-
VIII, showed two broad peaks of medium strength in the
range 5.3±0.2 and 8.3±0.2 degree2θ and one large peak
in the range 18-23 degree2θ with a maximum at about
18.3±0.2 degrees two-theta, instead of many peaks as
appeared in solvate-I and II. The XRPD of solvate-VIII
depicted one very small peak and another broad peak
suggesting the very low crystalline nature of this form.
The Figure 5 shows clear differences in the XRPD
pattern of the solvates compared with the commercial
sample.
These solvates were heated in a vacuum oven to gen-
erate desolvated forms and the XRPD pattern of these
desolvated forms (Figure 6) showed that the solvates
have converted to some new forms. The diffraction pat-
tern of solvate-I was found to be similar after desolva-
tion indicating that the crystal lattice has been retained
when isopropyl alcohol leaves the lattice but the crystal-
linity increased up to some extent. The XRPD pattern of
Solvate-II, III, IV, V and VIII indicated similar amorph-
ous halo pattern after removal of the entrapped solvent.
Based on this observation the solvates have been pro-
posed to be different pseudopolymorphs having iso-
morphic structure. This similarity in XRPD patterns
drug solvates having isomorphous nature of crystals has
been reported in literature [1]. The Solvate-VI shows a
different XRPD pattern and the new peaks observed are
attributed to its conversion to a new crystalline form
after desolvation. The XRPD pattern of solvate-VII after
desolvation reveals that the pattern becomes same to
that of the original sample indicating it has converted to
drug after desolvation.
Figure 4 Scanning electron micrographs of ATC and its solvates.
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The 13C /MAS solid state NMR spectra of ATC and its
crystal forms recrystallised from various organic solvents
were performed to futher confirm the presence of en-
trapped solvent in the crystal lattice of the solvate [17-20].
The peak assignments are based on the comparison withthe 1H and 13C NMR of dissolved atorvastatin (Figure 7).
The resulting spectra of solvate I, solvate III and solvate
VI of atorvastatin showed similar pattern, although notice-
ably distinct peaks for solvents were detected. In solvate I
peaks at position 28.9 and 64.7 are associated with CH3
and CH group of isopropyl alcohol (IPL) indicating the
Figure 5 XRPD pattern of ATC and its solvates.
Figure 6 XRPD pattern of ATC and its solvates after desolvation.
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http://journal.chemistrycentral.com/content/6/1/114presence of IPL in the solvate. The peaks at 16.9 and 58.9
in solvate III were most likely associated with ethanol
solvent in crystal lattice. The common peaks at 16.9 and
58.9 were associated with a CH3 group of ethanol. In solv-
ate VI peaks at 17.1 and 59.3 are also assigned to ethanol,
while peaks at 34.1 and 203.4 were associated with acet-
one. The sharpness of peaks between 60–80 ppm which
were assigned as C-8 and C-10 in solvate I,decreases in
the crystal form of solvate III and solvate VI. However, in
solvate II, solvate V the resolution of peaks was sharp. An
extra peaks at 29.1 and 76.4 were detected in the solvate II
which can be accounted for THF molecule. In solvate V
an extra sharp signal at 49.8 was assigned to methanol. In
solvate VII peaks at 16.1 and 58.3 are also assigned to
ethanol. In solvate VIII an extra sharp peaks at 14.5, 18.1,
34.3 and 62.6 were due to butanol. It is revealed from
13C /MAS solid state NMR spectra of solvate VIII, theresolution of peak were sharp indicating it to be crystal-
line. It is interesting to note that the CH3 has resonances
with different chemical shifts despite similar crystallo-
graphic packing. Thus, it is proposed that different
molecular structures or further packing of crystal
forms may be attributed to the residual solvent or
solvate molecule within the crystal forms [20].
Calorimetric studies
Microreaction-calorimetric studies were used to diffe-
rentiate the solvates by determining their heat capacity
as well as enthalpy of solutions.
Heat capacity
The comparison of molar heat capacities of solvates with
the drug gives information about the solvent molecule
within the condensed phase solvates. The heat capacity
Figure 7 13C /MAS solid state NMR spectra of ATC and its solvates (identified solvent resonances as star).
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given in Table 2.
ΔCPp ¼ Cp solvateð Þ  Cp drugð Þ þ xCp solventð Þ
 
ð2Þ
Cp(solvate) = molar heat capacity of solvate
Cp(drug) = molar heat capacity of atorvastatin calcium
Cp(solvent)) = molar heat capacity of solvent in the liquid
state (the value varies according to stoichiometry of
solvates)
X = ratio of the stoichiometry of solvent to drug.The comparison of molar heat capacities of solvates
with the anhydrous drug gives information about the
solvent molecule within the condensed phase solvates.
The heat capacity was found to be higher for the sol-
vated amorphate as compared to pure drug. The large
ΔCp for all the solvates suggest that they are present in
the lattice channels (Table 2).Enthalpy of solution
As indicated by XRPD studies these forms are low crys-
talline in nature and the extent of crystallanility varies.
The lattice energy was determined utilizing calorimetric





Molar heat capacity of
solvent (J/(mol.K) at 25°C
ΔCp at 25°C
(J/(mol.K)
Atorvastatin (anhydrous) (ATC) 1.25±0.014 1514.43±0.11 - -
Solvate- I (ATC + 0.5 Isopropyl alcohol) 1.96±0.024 2347.86±0.05 77.0 756.42
Solvate- II (ATC + THF) 2.07±0.003 2547.11±0.04 123.0 909.68
Solvate- III (ATC + Ethanol) 1.98±0.007 2383.56±0.02 112.4 756.72
Solvate- IV (ATC + 0.5 t-butanol) 2.44±0.004 2913.66±0.12 56.2 1343.02
Solvate- V (ATC + methanol) 2.23±0.019 2720.96±0.12 159.0 1047.52
Solvate-VI (ATC + 1 Acetone +0.5 Ethanol) 2.43±0.007 3009.49±0.05 181.7 1313.35
Solvate-VII (ATC + 0.5 Ethanol + Water) 1.83±0.011 2234.91±0.06 131.4 589.10
Solvate- VIII (ATC + 1- butanol) 2.30±0.008 2840.19±0.02 174.3 1151.49
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http://journal.chemistrycentral.com/content/6/1/114studies which determine the enthalpy of solution which
is closely associated with their lattice energy.
Molar enthalpy of solution (ΔHsol) was determined in
phosphate buffer (pH8) as well as in methanol. All the
solvates showed endothermic behavior in both phos-
phate buffer (pH8) and methanol (Table 3). The solvate-
VIII was least endothermic (2.475 kJ mol-1) suggesting it
to be most amorphous. The magnitude of molar enthalpy
of solution of ATC is found to be highest (21.89 kJ mol-1)
exhibiting minimum ease of molecular release from the
lattice.
As discussed above, the endothermic ΔHsol in buffer
and ΔHsol in methanol follows the order: solvate-VIII
(1-butanol solvate) < solvate-I (isoproplyate) < solvate-V
(methanol solvate) < solvate-III (ethonalate) < solvate-VI
(acetone ethanol solvate) < solvate-IV (t-butanol solvate) <
solvate-II (THF solvate) < solvate-VII (mixed hemi-etha-
nol hydrate) < ATC.
The enthalpies of solution for all the solvates is found
to be in the same order in both the solvents as indicatedTable 3 Enthalpies of solution in phosphate buffer (pH8) and












Atorvastatin Calcium (ATC) 0.166 − −
Solvate- I (ATC + 0.5
Isopropyl alcohol))
0.374 −24.45 −13.52
Solvate- II (ATC + THF) 0.192 −11.32 10.85
Solvate- III (ATC + Ethanol) 0.292 −7.61 32.06
Solvate- IV (ATC + 0.5
t-butanol)
0.225 3.16 34.85
Solvate- V (ATC + methanol) 0.341 2.12 16.35
Solvate-VI (ATC + 1
Acetone +0.5 Ethanol)
0.245 −10.80 41.20
Solvate-VII (ATC + 0.5
Ethanol + Water)
0.185 −4.25 112.49
Solvate- VIII (ATC + 1- butanol) 0.387 −4.6 13.36by a straight line observed in the plot between the en-
thalpies of solution in the two solvents confirming per-
fect correlation between two sets of data (Figure 8).
In order to determine the enthalpy associated with the
solvation process the enthalpy of solution of a particular
solvate was determined in its own solvent. The enthalpy
of solvation [21] was calculated by the equation (3) and
the values are given in Table 3.
ΔsolyH ¼ ΔsolH1  ΔsolH2 ð3Þ
ΔsolH
2 = enthalpy of solution of the drug
ΔsolH
1= enthalpy of solution of the solvate in solvent of
solvation
If we now consider the following thermodynamic cycle
(Figure 9).
The enthalpies of solution of the drug and the solvates,























Figure 8 Plot between enthalpy of solution of ATC solvates in
phosphate buffer pH8 and in Methanol.
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http://journal.chemistrycentral.com/content/6/1/114capacities of the drug, solvate and the solvent and fur-
ther assuming that heat capacities remain constant dur-
ing the temperature range 25°C to Tdesolv the enthalpy of
desolvation is given by the equation:
Δdesoly H ¼ ΔsolnH2  ΔsolnH1  ΔCP Tdesoly  25
 
þ 1=2 ΔyapH ð4Þ
The measured values of enthalpy of desolvation from
DSC and those calculated from equation (3) are com-
pared in Table 4. The agreement seems to be reasonable
in spite of several assumptions and the measured heat
capacity for the solvates may be Cs and not Cp.Figure 9 Thermodynamic cycle. (Where, x = ratio of the
stoichiometry of solvent to drug).Solubility Studies
The solubility studies of pure drug and various solvates
were performed in water and phosphate buffer pH 6.8 at
37°C and are given in table 3. The solubility study sug-
gests that the most amorphous form (solvate-VIII) was
most soluble (0.374±0.06 mg/ml) with a 2.07 times in-
crease in solubility in comparison to commercial sample
while the commercial sample which is crystalline was
least soluble.
Effect of ATC & various ATC solvates on lipid profile
In vivo studies in rats
Hypolipidemic drugs like ATC (HMG-CoA reductase
inhibitors) are known to reduce elevated total choles-
terol and TG levels in blood. At the same time they
cause elevation of the HDL-cholesterol levels, which
promote the removal of cholesterol from peripheral cells
and facilitate its delivery back to the liver. This phar-
macodynamic effect is reported to be dose dependent
hence, it was used as a basis for the comparison of in
vivo performance of ATC and its solvates. Administra-
tion of Triton significantly increased triglyceride and
total cholesterol levels in rats and leads to hypercholes-
terolemia. The test group showed significant decrease in
total cholesterol and in TG. Thus, solvate-I and solvate-
VIII performed better than pure ATC in reducing total
cholesterol and TG levels (Table 5 & Figure 10). This
could be primarily attributed to the improved solubility
associated with different forms between ATC and its
various solvates.
Triton significantly increased triglyceride and total
cholesterol levels in rats. ATC reduced lipid profile in
triton treated rats. However, solvate-VIII and solvate-I
showed better lipid lowering profile as compared to ator-
vastatin against triton-induced dyslipidemia.
Experimental
Recrystallization of the drug was carried out by dissol-
ving ATC in minimum amount of solvent mixtures at
temperature few degrees below the boiling point of
the solvent. The obtained suspension was stirred at am-
bient temperature for a sufficient time (24–48 hrs). The
saturated solution was then filtered while hot (0.45 μm
millipore microfilter) and were left to recrystallize by
spontaneous cooling and evaporation at room tempera-
ture. Recrystallized product obtained in a period of 15–21
days was isolated by suction filtration and dried at ambi-
ent temperature under vacuum prior to solid and liquid
state analysis. Based upon the solvents used for recrystali-
zation, the solvates were designated as solvate-I (hemi iso-
propylate), solvate-II (THF solvate), solvate-III (ethanol
solvate), solvate-IV (t-butanol solvate), solvate-V (metha-
nol solvate), solvate-VI (acetone ethanol solvate), solvate-
VII (hemi-ethanol hydrate) and solvate-VIII (1- butanol




Enthalpy of desolvation, ΔdesolvH
(kJ mol−1) calculated from equation 4
Atorvastatin (ATC) -
Solvate- I (ATC + 0.5 Isopropyl alcohol) 24.20 25.93
Solvate- II (ATC + THF) 51.47 57.17
Solvate- III (ATC + Ethanol) 44.69 34.39
Solvate- IV (ATC + 0.5 t-butanol) 78.85 78.31
Solvate- V (ATC + methanol) 26.27 26.70
Solvate-VI (ATC + 1 Acetone +0.5 Ethanol) 56.74 52.01
Solvate-VII (ATC + 0.5 Ethanol + Water) 104.64 103.96
Solvate- VIII (ATC + 1- butanol) 28.56 31.81
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generate desolvated forms. Solvate I, Solvate II and Solvate
VII was heated upto 120°C; Solvate III, Solvate IV, Solvate
V, Solvate VI was heated upto 110°C and Solvate VIII was
heated up to 130°C. The each form was heated in a vac-
uum oven for 4 hours.
Thermal analysis
DSC thermograms were obtained on DSC, Q20, TA
Instruments-Waters LLC, USA. The calorimeter was ca-
librated for temperature and heat flow accuracy using
the melting of pure indium (mp 156.6°C and ΔH of
25.45 Jg−1). A mass between 2–8 mg was taken into the
aluminium pan, covered with lid and sealed. DSC curves
were obtained under a nitrogen purge of 50 mL per mi-
nute at a heating rate of 10°C per minute with the tem-
perature range from 50-350°C.
Loss of solvent from the samples was characterized by
TGA obtained by TA Instruments-Waters LLC, USA.
TGA traces were recorded at heating rates of 10°C per
minute under a nitrogen purge of 50 ml per minute. Sam-
ples with masses between 1–10 mg were analyzed using
platinum pan. Mass loss (%) was calculated based on the
mass of the original sample.Table 5 Effect of ATC & various ATC solvates on lipid
profile
Groups Triglyceride (mg/dl) Total Cholesterol (mg/dl)
I Control 71.3 84
II Triton 426 357
III ATC 169 198
IV Solvate I 143 161
V Solvate II 170 201
VI Solvate III 172 203
VII Solvate IV 168 204
VIII Solvate V 170 198
IX Solvate VI 174 197
X Solvate VII 167 202
XI Solvate VIII 140 152Gas chromatography–mass spectrometry (GC-MS)
Analysis
GC-MS analysis was carried out on a GC Clarus 600
Perkin Elmer system equipped with head space turbo
matrix-16 and AOC-20i autosampler. Gas chromatograph
interfaced to a mass spectrometer (GC-MS) instrument
employing the following conditions: Column Elite-1 fused
silica capillary column (30 mm×0.25 mm ID ×1 μM
df, composed of 100% Dimethyl poly siloxane), oper-
ating in electron impact mode at 70 eV; helium
(99.999%) was used as carrier gas at a constant flow
of 1ml/min and an injection volume of 0 μl was
employed (split ratio of 50:1) injector temperature 250°C;
ion-source temperature 280°C. The oven temperature was
programmed from 35°C (isothermal for 8 min), with an
increase of 10°C/min, to 150°C, hold 2 min then 5°C/min
to 200°C. Mass spectra were taken at 70 eV; a scan interval
of 0.5 seconds and fragments from 30 to 200 Da.
Nuclear Magnetic Resonance (NMR) Spectroscopy
NMR spectra were obtained in deuterated D2O on Bruker
Advance II 400 NMR spectrometer operating at 400 Hz.
X-Ray powder diffraction Analysis
The powder diffraction patterns were recorded on an
X-ray diffractometer (XPERT-PRO, PAN analytical,
Netherlands, Holand) with Cu as tube anode. The dif-
fractograms were recorded under following conditions:
voltage 40 kV, 35 mA, angular range 5 and fixed diver-
gence slit change. Care was taken to avoid crystal changes
during sample preparation. Approximately 200 mg of
samples were loaded into the sample holder, taking care
not to introduce preferred orientation of the crystals.
Solid State Nuclear Magnetic Resonance spectroscopy
(SSNMR)
The solid state 13C cross-polarization magic angle spin-
ning (CP-MAS) spectra were acquired using a Bruker
DSX-300 NMR spectrometer using a 5 mm double re-
sonance CP-MAS probe. The 13C resonance frequency is
Figure 10 Graph representation of effect of ATC & various solvates on lipid profile Concentration (mg/dl).
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spectral width of 18.8 kHz, 1130 complex data points,
acquisition time 30 ms, contact time 2 ms. A total of
1024 scans were acquired with a relaxation delay 4 s. All
the spectra were referenced to tetramethylsilane (TMS)




Heat capacity measurements were performed on Micro-
reaction calorimeter obtained from Thermal Hazards
Technology, UK. The size of sample used in analysis
ranged from 100-150 mg and was weighed (Sartorius
Model CP225D) into a glass vial. The empty vial was
placed as the reference sample. A temperature step of 2
C is then applied to the system and the heat required is
measured. The experiment is then repeated in the re-
verse direction to verify the measurement. A measure-
ment with empty vial was conducted first to ensure any
difference between the heat capacity of the vials is
accounted for. The heat capacity for ATC and all the
solvates was conducted at 25°C (24-26°C).
Enthalpy of solution measurements
Calorimetric studies were performed on Microreaction
calorimeter obtained from Thermal Hazards Technol-
ogy, UK. Two different solvents, viz, the phosphate buf-
fer (pH 2) and methanol were used to determine the
enthalpy of solution and the measurements were per-
formed at 25°C. The size of sample used in this study
ranged from 10 to 20 mg and was weighed (Sartorius
Model CP225D) into a cylindrical glass tube covered
with parafilm on one side. This cylindrical tube was sub-
merged into the ampoule containing the solvent. A plun-
ger with a cap was put from the open end of the tube. The
same solvent was put into the reference ampoule. Thesewere put into the sample and reference holes until both
rest on the base of the holes. The apparatus was maintai-
ned at constant temperature at 25°C (±0.0005°C). The pa-
rafilm was shattered mechanically by means of plunger.
Aqueous solubility measurement
MSW-275 (Macro scientific works, New Delhi) shaker
was used for measuring aqueous solubility of solvates of
ATC. Solubility studies were performed by adding 10 mg
of ATC or its solvates in flasks containing 10 mL of
phosphate buffer pH 6.8. The mixtures were shaken at
37°C for 24 h. The aliquots were filtered through 0.45 μm
membrane filter and analyzed spectrophotometrically at
242 nm. The standard plot of ATC was prepared by dis-
solving a weighed amount of the drugs in phosphate buf-
fer pH 6.8, suitably diluted and absorbances taken at
wavelength 242 nm on a spectrophotometer. E1% 1cm
was calculated.
Conclusion
The study provides insights into the thermal characte-
rization of ATC and its various forms. The characteriza-
tion of crystalline solvated forms of ATC has suggested
the formation of eight solvates by entrapment of the
solvent molecules in the cavities formed by the host
drug. The amounts of organic solvents in these forms as
drug substances were below the limit regulated by the
ICH guideline Q3C on residual solvents in pharmaceuti-
cals [22]. The GC-MS analysis established the solvent
associated with ATC as mixtures of solvents have been
used for recrystallization of the solvates. The solvent
molecules incorporated into the drug molecule were de-
tected by 13CP/MAS solid state NMR spectroscopy. 13C
Solid state NMR provides an excellent advantage over
other techniques in its ability to distinguish different sol-
vates of very similar crystallographic structure. All the
forms were endothermic in phosphate buffer pH8. The
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solvates. The hypolipidemic activity study indicated solv-
ate I and VIII to be most effective in reducing the choles-
terol and triglyceride levels. This could be primarily
attributed to the improved solubility associated with these
solvates in comparison to ATC and its various solvates.
Methods
Drugs and reagents
Triton was purchased from Sigma (St. Louis, MO, USA).
Atorvastatin was obtained as gift sample from Ind-Swift
Lab, Mohali. Triglyceride and total cholesterol kits were
procured from Span Diagnostics.
In vivo studies in rats
Animals
The hypolipidemic activity of ATC and its different sol-
vates was determined in male Wistar rats (220–260 g)
bred in Central Animal House facility of Panjab University.
The rats were housed under optimal laboratory condi-
tions, maintained on 12 h light and dark cycle and had free
access to food (Hindustan Lever Products, Kolkata, India)
and water. Animals were acclimatized to laboratory condi-
tions before the tests. All experiments were carried out be-
tween 0900 and 1700 h. The experimental protocols were
approved by the Institutional Animal Ethics Committee
and conducted according to the Indian National Science
Academy guidelines for the use and care of animals.
Induction and assessment of cholesterol
Fifty five male Wistar rats were divided into the follo-
wing 11 groups containing 5 animals in each group:
Group I. Control (Normal saline)
Group II. Triton (200 mg/kg, i.p.) induced
hyperlipidemia
Group III. Triton treated rats received ATC
(30 mg/kg, oral gavage)
Group IV. Triton treated rats received ATC S1
(30 mg/kg, oral gavage)
Group V. Triton treated rats received ATC-S2
(30 mg/kg, oral gavage)
Group VI. Triton treated rats received ATC-S3
(30 mg/kg, oral gavage)
Group VII. Triton treated rats received ATC-S4
(30 mg/kg, oral gavage)
Group VIII. Triton treated rats received ATC-S5
(30 mg/kg, oral gavage)
Group IX. Triton treated rats received ATC-S6
(30 mg/kg, oral gavage)
Group X. Triton treated rats received ATC-S7
(30 mg/kg, oral gavage)
Group XI. Triton treated rats received ATC-S8
(30 mg/kg, oral gavage)Atrovastain and various solvates were freshly suspen-
ded in 0.5% carboxymethyl cellulose and administered
by oral gavage. Two hours later, all groups except con-
trol animals received intraperitonial injection of Triton
(100 mg/kg). Eighteen hours after triton injection, blood
was collected from tail vein. Plasma was separated and
stored at −20°C for further biochemical analysis. Total
cholesterol and triglyceride were analyzed in plasma
samples using diagnostic kits as per manufacturer
instructions.
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Additional file 1: Figure S1. 1H NMR of ATC (liquid state) and its
solvates.
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